Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus R-CHOP for First-line PMBCL
NCT06412068Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in primary mediastinal large B-cell lymphoma (PMBCL), sponsored by Sun Yat-sen University. Primary endpoints: Complete Remission at 2 years and Overall Response Rate at 2 years. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT06412068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06412068.